Antitumor effect of XCT790, an ERR α inverse agonist, on ERα-negative endometrial cancer cells

ConclusionsFrom our data we conclude that XCT790 has an anti-tumor effect on endometrial cancer cells in vitro and in vivo. As such, it may serve as a novel therapeutic agent for endometrial cancer.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research